The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1467
ISSUE1467
April 27, 2015
Umeclidinium (Incruse Ellipta) for COPD
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Umeclidinium (Incruse Ellipta) for COPD
April 27, 2015 (Issue: 1467)
The FDA has approved Incruse Ellipta (GSK), a
single-agent inhaler containing the long-acting
anticholinergic umeclidinium, for once-daily maintenance
treatment of chronic obstructive pulmonary
disease (COPD). Umeclidinium was initially...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.